The use of a biologic topical haemostatic agent (TachoSil®) for the prevention of postoperative bleeding in patients on antithrombotic therapy undergoing thyroid surgery: A randomised controlled pilot trial

International Journal of Surgery

Volumn 20, Issue , 2015, Pages 95-100

  Erdas, Enrico ^a   Medas, Fabio ^a   Podda, Francesco ^a   Furcas, Silvia ^a   Pisano, Giuseppe ^a   Nicolosi, Angelo ^a   Calò, Pietro Giorgio ^a  

^a DEPARTMENT OF RADIOLOGY   (Italy)

Author keywords

Antithrombotic drugs; Postoperative bleeding; Thyroid surgery; Topical haemostatic agents

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FIBRINOGEN PLUS THROMBIN; WARFARIN; BIOLOGICAL PRODUCT; DRUG COMBINATION; FIBRINOGEN; FIBRINOLYTIC AGENT; HEMOSTATIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; VITAMIN K GROUP;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CAUTERIZATION; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG COST; DRUG WITHDRAWAL; ECCHYMOSIS; FEMALE; FOLLOW UP; HEMATOMA; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; INTERNATIONAL NORMALIZED RATIO; MALE; MECHANICAL HEART VALVE; MIDDLE AGED; PILOT STUDY; POSTOPERATIVE CERVICAL HEMATOMA; POSTOPERATIVE HEMORRHAGE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSTHETIC VALVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT LARYNGEAL NERVE PALSY; SECONDARY PREVENTION; SURGICAL INFECTION; THYROIDECTOMY; TOPICAL TREATMENT; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; AGONISTS; CHEMICALLY INDUCED; DRUG COMBINATION; PROSPECTIVE STUDY; SURGERY; THYROID GLAND; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; ASPIRIN; BIOLOGICAL PRODUCTS; DRUG COMBINATIONS; FEMALE; FIBRINOGEN; FIBRINOLYTIC AGENTS; HEMOSTATICS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDIES; THROMBIN; THYROID GLAND; THYROIDECTOMY; VITAMIN K;

EID: 84938814617     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2015.06.027     Document Type: Article

References (42)

1. Skolarus L.E., Morgenstern L.B., Froehlich J.B., Lisabeth L.D., Brown D.L. Guideline-discordant periprocedural interruptions in warfarin therapy. Circ. Cardiovasc. Qual. Outcomes 2011, 4:206-210.
2. Cruden N.L., Harding S.A., Flapan A.D., Graham C., Wild S.H., Slack R., Pell J.P., Newby D.E. Scottish Coronary Revascularisation Register Steering Committee, previous coronary stent implantation and cardiac events in patients undergoing non-cardiac surgery. Circ. Cardiovasc. Interv. 2010, 3:236-242.
3. th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl. l). American College of Chest Physicians, e326S-50S.
4. Douketis J.D. Perioperative management of warfarin therapy: to bridge or not to bridge, that is the question. Mayo Clin. Proc. 2008, 83:628-629.
5. Harrison R.W., Ortel T.L., Becker R.C. To bridge or not to bridge: these are the questions. J. Thromb. Thrombolysis 2012, 34:31-35.
6. Darvish-Kazem S., Gandhi M., Marcucci M., Douketis J.D. Perioperative management of antiplatelet therapy in patients with a coronary stent who need non-cardiac surgery: a systematic review of clinical practice guidelines. Chest 2013, 144:1848-1856.
7. Ferraris V.A., Saha S.P., Oestreich J.H., Song H.K., Rosengart T., Reece T.B., Mazer C.D., Bridges C.R., Despotis G.J., Jointer K., Clough E.R. Society of Thoracic Surgeons, 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and non-cardiac operations. Ann. Thorac. Surg. 2012, 94:1761-1781.
8. Oprea A.D., Popescu W.M. Perioperative management of antiplatelet therapy. Br. J. Anaesth. 2013, 1(111 Suppl. l):i3-17.
9. Sanders D.L., Shahid M.K., Ahlijah B., Raitt J.E., Kingsnorth A.N. Inguinal hernia repair in the anticoagulated patient: a retrospective analysis. Hernia 2008, 12:589-592.
10. Sfakianos J.P., Hakimi A.A., Kim P.H., Zabor E.C., Mano R., Bernstein M., Karellas M., Russo P. Outcomes in patients undergoing nephrectomy for renal cancer on chronic anticoagulation therapy. Eur. J. Surg. Oncol. 2014, 40:1700-1705.
11. Sulu B., Aytac E., Stocchi L., Vogel J.D., Kiran R.P. The minimally invasive approach is associated with reduced perioperative thromboembolic and bleeding complications for patients receiving preoperative chronic oral anticoagulant therapy who undergo colorectal surgery. Surg. Endosc. 2013, 27:1339-1345.
12. Lazio B.E., Simard J.M. Anticoagulation in neurosurgical patients. Neurosurgery 1999, 45:838-847.
13. Della Valle C.J., Jazrawi L.M., Idjadi J., Hiebert R.N., Stuchin S.A., Steiger D.J., Di Cesare P.E. Anticoagulant treatment of thrombo-embolism with intravenous heparin therapy in the early postoperative period following total joint arthroplasty. J. Bone Jt. Surg. Am. 2000, 82:207-212.
14. Jamula E., Anderson J., Douketis J.D. Safety of continuing warfarin therapy during cataract surgery: a systematic review and meta-analysis. Thromb. Res. 2009, 124:292-299.
15. Perera A.H., Patel S.D., Law N.W. Thyroid surgery as a 23-hour stay procedure. Ann. R. Coll. Surg. Engl. 2014, 96:284-288.
16. Snyder S.K., Hamid K.S., Roberson C.R., Rai S.S., Bossen A.C., Luh J.H., Scherer E.P., Song J. Outpatient thyroidectomy is safe and reasonable: experience with more than 1,000 planned outpatient procedures. J. Am. Coll. Surg. 2010, 210:575-582.
17. Seybt M.W., Terris D.J. Outpatient thyroidectomy: experience in over 200 patients. Laryngoscope 2010, 120:959-963.
18. Lang B.H., Yih P.C., Lo C.Y. A review of risk factors and timing for postoperative hematoma after thyroidectomy: is outpatient thyroidectomy really safe?. World. J. Surg. 2012, 36:2497-2502.
19. Campbell M.J., McCoy K.L., Shen W.T., Carty S.E., Lubitz C.C., Moalem J., Nehs M., Holm T., Greenblatt D.Y., Press D., Feng X., Siperstein A.E., Mitmaker E., Benay C., Tabah R., Oltmann S.C., Chen H., Sippel R.S., Brekke A., Vriens M.R., Lodewijk L., Stephen A.E., Nagar S., Angelos P., Ghanem M., Prescott J.D., Zeiger M.A., Aragon Han P., Sturgeon C., Elaraj D.M., Nixon I.J., Patel S.G., Bayles S.W., Heneghan R., Ochieng P., Guerrero M.A., Ruan D.T. A multi-institutional international study of risk factors for hematoma after thyroidectomy. Surgery 2013, 154:1283-1289.
20. Calò P.G., Erdas E., Medas F., Pisano G., Barbarossa M., Pomata M., Nicolosi A. Late bleeding after total thyroidectomy: report of two cases occurring 13 days after operation. Clin. Med. Insights Case Rep. 2013, 6:165-170.
21. Wright J.D., Ananth C.V., Lewin S.N., Burke W.M., Siddiq Z., Neugut A.I., Herzog T.J., Hershman D.L. Patterns of use of hemostatic agents in patients undergoing major surgery. J. Surg. Res. 2014, 186:458-466.
22. Amit M., Binenbaum Y., Cohen J.T., Gil Z. Effectiveness of an oxidized cellulose patch hemostatic agent in thyroid surgery: a prospective, randomized, controlled study. J. Am. Coll. Surg. 2013, 217:221-225.
23. Emilia M., Luca S., Francesca B., Luca B., Paolo S., Giuseppe F., Gianbattista B., Carmela M., Luigi M., Mauro L. Topical hemostatic agents in surgical practice. Transfus. Apher. Sci. 2011, 45:305-311.
24. Haas S. The use of a surgical patch coated with human coagulation factors in surgical routine: a multicenter post-authorization surveillance. Clin. Appl. Thromb. Hemost. 2006, 12:445-450.
25. Rickenbacher A., Breitenstein S., Lesurtel M., Frilling A. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery-a systematic review. Expert Opin. Biol. Ther. 2009, 9:897-907.
26. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM207483.pdf.
27. Rosato L., Avenia N., Bernante P., De Palma M., Gulino G., Nasi P.G., Pelizzo M.R., Pezzullo L. Complications of thyroid surgery: analysis of a multi-centric study on 14,934 patients operated on in Italy over 5 years. World J. Surg. 2004, 28:271-276.
28. Calò P.G., Pisano G., Piga G., Medas F., Tatti A., Donati M., Nicolosi A. Postoperative hematomas after thyroid surgery. Incidence and risk factors in our experience. Ann. Ital. Chir. 2010, 81:343-347.
29. Harding J., Sebag F., Sierra M., Palazzo F.F., Henry J.F. Thyroid surgery: postoperative hematoma-prevention and treatment. Langenbecks Arch. Surg. 2006, 391:169-173.
30. Witt D.M., Delate T., Garcia D.A., Clark N.P., Hylek E.M., Ageno W., Dentali F., Crowther M.A. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch. Intern. Med. 2012, 172:1484-1491.
31. Biondi-Zoccai G.G., Lotrionte M., Agostoni P., Abbate A., Fusaro M., Burzotta F., Testa L., Sheiban I., Sangiorgi G. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur. Heart J. 2006, 27:2667-2674.
32. Dunn A.S., Spyropoulos A.C., Turpie A.G. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J. Thromb. Haemost. 2007, 5:2211-2218.
33. Siegal D., Yudin J., Kaatz S., Douketis J.D., Lim W., Spyropoulos A.C. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012, 126:1630-1639.
34. Tafur A.J., McBane R., Wysokinski W.E., Litin S., Daniels P., Slusser J., Hodge D., Beckman M.G., Heit J.A. Predictors of major bleeding in peri-procedural anticoagulation management. J. Thromb. Haemost. 2012, 10:261-267.
35. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., Rickles F.R., Julian J.A., Haley S., Kovacs M.J., Gent M. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) Investigators, low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N. Engl. J. Med. 2003, 349:146-153.
36. Ginsberg J.S., Chan W.S., Bates S.M., Kaatz S. Anticoagulation of pregnant women with mechanical heart valves. Arch. Intern. Med. 2003, 163:694-698.
37. Wright J.D., Ananth C.V., Lewin S.N., Burke W.M., Siddiq Z., Neugut A.I., Herzog T.J., Hershman D.L. Patterns of use of hemostatic agents in patients undergoing major surgery. J. Surg. Res. 2014, 186:458-466.
38. Achneck H.E., Sileshi B., Jamiolkowski R.M., Albala D.M., Shapiro M.L., Lawson J.H. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann. Surg. 2010, 251:217-228.
39. Emilia M., Luca S., Francesca B., Luca B., Paolo S., Giuseppe F., Gianbattista B., Carmela M., Luigi M., Mauro L. Topical hemostatic agents in surgical practice. Transfus. Apher. Sci. 2011, 45:305-311.
40. Rickenbacher A., Breitenstein S., Lesurtel M., Frilling A. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery-a systematic review. Expert. Opin. Biol. Ther. 2009, 9:897-907.
41. Singer M.C., Iverson K.C., Terris D.J. Thyroidectomy-related malpractice claims. Otolaryngol. Head Neck Surg. 2012, 146:358-361.
42. Schulte K.M., Röher H.D. Behandlungsfehler bei Operationen der Schilddrüse. Chirurg 1999, 70:1131-1138.